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Transfection by cationic gemini surfactants 
M. Damen,a A. J. J. Groenen,a S. F. M. van Dongen,a R. J. M. Nolte,a B. J. Scholte,b and M. C. Feitersa 
Abstract: Diseases that are linked to defective genes or mutations can in principle be cured by gene therapy, in which 
damaged or absent genes are either repaired or replaced by new DNA in the nucleus of the cell. Related to this, disorders 
associated with elevated protein expression levels can be treated by RNA interference via the delivery of siRNA to the 
cytoplasm of cells. Polynucleotides can be brought into cells by viruses, but this is not without risk for the patient. 
Alternatively, DNA and RNA can be delivered by transfection, i. e. by non-viral vector systems such as cationic surfactants, 
which are also referred to as cationic lipids. In this review, recent progress on cationic lipids as transfection vectors will be 
discussed, with special emphasis on geminis, surfactants with 2 head groups and 2 tails connected by a spacer. 
1. Introduction 
The technique of introducing nucleic acids into eukaryotic cells 
is called transduction when virus-mediated, and transfection 
when achieved by non-viral methods. Such techniques are not 
only important as research tools, but also find application in 
gene therapy. This has the potential to treat almost any 
hereditary disease because it aims to address a known defect: 
malfunctioning genes can be repaired directly by the delivery 
of functional DNA into the nucleus of a cell.1,2 Promising results 
have been obtained in recent gene therapy clinical trials in 
diverse areas like cancer3 and diseases of the blood,4 eye,5 and 
brain.6 Gene therapy can be implemented directly to cells in 
the body of the patient, or by way of stem cells that are 
removed from the patient and incorporated after 
transfection.7-9 Using the same or similar carriers10,11 cells can 
also be transfected by RNA instead of DNA, using in vitro 
transcribed mRNA to achieve protein expression.12-14 An even 
more powerful approach is the delivery of siRNA (small 
interfering RNA) as part of an RNAi (RNA interference) 
strategy,15-18 in which the delivery of short double stranded 
RNA segments (20 to 25 base pairs) can silence the matching 
genes, i.e. block their transcription by formation of a RNA-
induced silencing complex, thereby shutting down their 
activity (Figure 1).19  
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Schematic representation of the RNAi strategy.19 
 
Viral vectors are currently the most commonly used 
vectors in clinical trials, and viral gene therapy has been 
approved in China since 2003, and in Europe since 2013.1 
Lentiviral (LV) vectors capable of integration of a therapeutic 
gene stably into the host genome were successfully 
developed.20 The 1st and 2nd generation LV vectors were 
incomplete retroviruses in which a therapeutic gene had been 
introduced, but they gave problems due to potential 
recombination with host viral sequences, replication, toxicity 
and immunogenicity.21,22 These problems are essentially 
solved in the 3rd generation LV vectors, which have led to 
many preclinical systems.23 Clinical application is however still 
hampered by safety concerns caused by random integration in 
the host genome, lack of efficiency of the available 
pseudotyped vectors, and the cost of clinical grade production 
of large batches of vector.24 The first viral systems developed 
for clinical use were adenoviral vectors, but they proved highly 
immunogenic and limited in topism and efficacy. Vectors 
derived from adeno-associated viruses are considered less 
immunogenic, can be produced in sufficient quantities, albeit 
at considerable cost, and have reached the stage of clinical 
trial and FDA approval.25,26  
Because of the safety and cost problems of viral vectors  
there is an interest in non-viral vector systems. While such 
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systems are hindered by (intra)cellular barriers and immune 
defence mechanisms against which viruses have evolved 
means to overcome, they can be made biocompatible and 
produced at low cost, and are easy to use.27 Non-viral delivery 
systems for DNA and RNA28 include cationic surfactants, also 
known as cationic lipids,29-33 but also cyclodextrins,34 and 
polymers such as polyethylenimine (PEI),35 dendrimers such as 
G2-octaamine,36 and materials related to carbon 
nanotubes.10,22 Non-viral carriers are now applied in a large 
number of clinical trials,37 with a share for cationic 
surfactants30,38,39 of 6 %.2 Before addressing lipid carriers in 
detail, we will first discuss general properties of lipids and 
barriers in transfection. 
Amphiphiles (molecules with one or more polar, 
hydrophilic head groups and apolar, hydrophobic tails) are 
only sparingly soluble in water, and above a certain 
concentration, the Critical Aggregate Concentration (CAC), 
they will form aggregates, in which the polar head groups are 
in contact with the solvent, whereas the tails will interact with 
each other, due to the hydrophobic effect.40 The packing 
parameter P relates the volume (V) of an amphiphilic molecule 
to its length (l) and head group area (a), via the equation P = V 
/ a . l, and determines what kind of aggregate (P < 1/3, micelle; 
1/3 < P < 1.2, cylindrical micelle; ½ < P < 1, vesicle; P = 1, 
bilayers, or P > 1, inverted micelle) will be formed.41-42 Glycerol 
is the most important linker between polar head groups and 
hydrophobic tails in biological lipids, such as the 
phospholipids.43 The phosphatidyl cholines (PC, Table 1), the 
most important class of lipids (50 %) in biological membranes, 
have a P value close to 1, and will therefore aggregate into a 
lamellar structure, such as a lipid bilayer. The phosphatidyl 
ethanolamine (PE, Table 1) head group is just a little bit smaller 
that than of PC, resulting in P > 1, so that inverted micelles are 
the preferred aggregate of this amphiphile in water. Dispersion 
in water induces liquid-crystalline order in the bilayers; below 
the phase transition temperature Tc they are in a rigid state, 
above it in a fluid state. The introduction of tails with 
unsaturation, such as the oleoyl (C18:1) tails, also present in 
DOPE (see Table 1), lowers Tc and increases the fluidity. 
The DNA of eukaryotic cells, which has a length of the 
order of mm when fully stretched, is condensed to a size (m 
range) compatible with that of the cell nucleus primarily by 
compaction in chromatin, which consists of nucleosomes.44 
These are formed by the electrostatic interaction of the 
negatively charged DNA with the histone proteins,45 which are 
rich (30-40 %) in the basic amino acids lysine and arginine. In 
specialized cells like the spermatozoa, the role of the histones 
is taken over by smaller proteins, the so-called protamines, 
which are rich in arginine, and by polyamines like spermidine 
and spermine (see section 2.2).  
Transfection can be regarded as a special problem in drug 
delivery. Mechanistically, the introduction of new genes or 
siRNA through non-viral vectors is not straightforward; 
multiple barriers need to be overcome (Figure 2).46-49 Delivery 
starts with complexation and condensation of the polynucleic 
acid by the cationic lipid aggregate into a so-called lipoplex,30-
31 which then interacts with the cell plasma membrane by 
electrostatic attraction to proteoglycans on the cell surface. 
The lipoplex enters the cell by endocytosis, via an endosome. 
From this the nucleic acids should escape to avoid being 
degraded, by lysosomal DNA-se, when the pH is lowered by 
the action of ATP-ases which convert the endosome to a 
lysosome. DNA then needs to travel through the cytoplasm 
and enter the nucleus so that it can reach the appropriate 
transcription machinery; the transfection of non-dividing cells 
is problematic.50 The release of siRNA from the lipoplex is 
much easier, since the molecule is much smaller than a DNA 
gene;51 because it can directly perform its therapeutic action in 
the cytosol, the nuclear entry does not present an additional 
hurdle. 
It can be concluded that the following aspects are 
important: i) for a lipid carrier to be able to assist the passage 
of polynucleotides over the biological membrane, it should be 
compatible with it, which is most likely when it has 2 aliphatic 
tails, and ii) compaction of the DNA is promoted by multivalent 
cationic head groups. The emphasis in this overview will be on 
the development of multivalency, in which the so-called 
gemini surfactants, to be discussed in detail in section 3, play 
an important role. A complication in the comparison of the 
merits of the various transfection procedures are the 
variations in i) the standards used, ranging from the early lipid 
DOTMA 1, via LipofectinTM, TransfectamTM, LipofectamineTM, 
and Lipofectamine 2000TM,39 to Lipofectamin PLUS 2000TM, ii) 
the use and choice of helper lipids, iii) the gene incorporated 
(often luciferase and/or -galactosidase), or to be silenced, iv) 
the targeted cells (overview in Supporting Information, Table 
S1), and v) the cell viability measurements. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Steps and barriers to overcome in gene delivery with 
non-viral vectors.31,52-3 
2. Lipid-based Vectors 
Lipid-mediated gene therapy was one of the earliest successful 
strategies used to introduce exogenous genetic material into 
host cells; it has received positive evaluations in clinical 
applications39 and favourable reviews in comparative studies 
of available reagents.37,55,56 Structure-activity relationships of 
early cationic lipopolyamines showed two trends. First, the 
density and nature of the cationic head group both affect the 
transfection; generally, a reduced charge density results in the 
formation of larger cationic complexes and lower toxicity.57 
Second, for a given head group, the outcome of a change in 
the hydrophobic portion on transfection is difficult to 
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predict;58 most successful cationic lipids as vectors for 
transfection, however, contain at least one unsaturation.59,60 
Unfortunately, increasing the cationic character of the lipids 
also increased their toxicity, a feature already known for PEI.61 
Neither head nor tail is the sole determinant of transfection 
efficiency; both domains have to be taken into consideration. 
Unfortunately, the combination of a ‘best head group’ and a 
‘best alkyl tail’ will not automatically result in the cationic lipid 
with the best general transfection activity. 
 
2.1. (Pseudo-)glyceryl Lipids and Terpenoids 
Many lipid carriers for transfection take cationic analogues 
of phospholipids (1, Table 1), the ‘pseudoglyceryl’ 
compounds62 2, in which the phosphate ester in the 1-position 
is replaced by a nitrogen-based cationic group, as a starting 
point, because of the expected compatibility with the plasma 
membrane. The positively charged head group has a dual 
function: it compensates the negative charge of the phosphate 
groups of the polynucleotides and plays a role in the 
association between lipoplexes and cells. The term 
‘lipofection’ was coined63 to describe lipid-based gene 
transfection, viz. of COS-7 (African green monkey kidney 
ﬁbroblast) and CV-1 cells with chloramphenicol acetyl 
transferase (CAT), using 1,2-dioleyl-3-trimethylammonium-
propane (DOTMA, 2a; Table 1) in combination with the so-
called helper lipid DOPE (1a) in a weight ratio  (= cationic 
lipid/{cationic lipid + helper lipid}) of 0.5, a combination 
commercialized as LipofectinTM; 2a was also the first lipid to be 
used for RNA transfection, viz. of NIH 3T3 cells with luciferase 
mRNA.64 Its observed toxicity was ascribed to the poor 
biodegradability of the lipid’s ether bonds; replacement by 
ester bonds gave 1,2-di-(9Z-octadecenoyl)-3-
trimethylammonium-propane (DOTAP, 2b),65 which is more 
easily degraded in vivo and therefore less toxic, although it is 
not necessarily always the better transfection agent. It is 
worth noting that contrary to their biological analogues, the 
pseudoglyceryl molecules are racemic, and neither 
enantioselective synthesis nor separation of the enantiomers 
to study their biological activities separately have been 
attempted; because the lipids are adjuvants, this is considered 
to be less important than if they would be themselves the 
therapeutically active molecules. 
It is not necessary that a permanent charge, as in a 
quaternary ammonium group, is present in the molecule; lipids 
with a procationic (protonable) group such as in a tertiary 
amine are also applicable. The lipoplex of DODAP 3a (apparent 
pKa 5.8) with DNA could be formed at pH 4 and appeared in 
the cryo-electron microscope as multilamellar vesicles, 
probably with DNA between the lipid layers; it could be 
administered at physiological pH provided that a PEGylated 
lipid was added to prevent aggregation, and was eliminated 
from plasma significantly more slowly than free DNA or a 
lipoplex with a quaternary aminolipid.66 Of a number of 
cationic lipids that were combined with fusogenic and PEG-
lipids as well as siRNA to give so-called Stabilized Nucleic Acid 
Lipid Particles (SNALP), the polyunsaturated acyl analogue of 
DODAP, DLinDMA 3b, was found to be the most active in 
silencing Neuro2A (mouse) cells transfected with luciferase 
with siRNA.60 This was also the cationic component in the 
SNALP used to silence apolipoprotein B in non-human 
primates.67 The activity could be further improved by installing 
a ketal group in the linker (DLin-K-DMA, 4a), and even more by 
incorporating additional methylene groups between ketal and 
ionisable head group (DLin-K2-DMA, 4b), resulting in effective 
suppression of the murine clotting factor VII in mouse 
hepatocytes by siRNA in the order 4b > 4a > 3a > DLinDAP 3b.68 
Even more active remote analogues are DLin-MC3-DMA 
5a69,70and its analogue L319 5b with a hydrolysable alkyl tail,71 
which however are no longer (pseudo)glyceryl compounds 
(Table 1B). 
 
Table 1. (Pseudo)glyceryl (A) and related lipids (B, C). 
A R1 Head 
group 
R2, 
R3   
Example Name 
H3N
+(CH2)2O(PO2
-)O- 
(phosphatidyl 
ethanolamine, PE) 
acyl oleoyl DOPE, 1a 
acyl oleoyl 
(palmitoyl 
+ oleoyl) 
stearoyl 
DOPC, 1b 
POPC, 1c 
 
DSPC, 1d 
Me3N
+(CH2)2O(PO2
-)O- 
(phosphatidyl choline, PC) 
Me3N
+- (Cl-) alkyl oleyl DOTMA, 2a 
acyl oleoyl DOTAP, 2b 
Me2N- acyl oleoyl DODAP, 3a 
 
 
 
 
alkyl linoleyl DLinDMA, 3b 
acyl linoleoyl DLinDAP, 3c 
acyl palmitoyl 6 
DLin-KCn-MC3-DMA, R = linoleyl 
5a 
L319, 5b,  
R = 
B R = linoleyl  
DLin-K-DMA, n = 1, 4a 
DLin-KCn-DMA, n = 2, 4b 
    C 
 
 
Another interesting modification of phospholipids is that 
with nucleosides to give nucleolipids, which combine the 
molecular recognition principles seen in a DNA helix with the 
self-assembly characteristics of lipids, and feature hydrogen 
bonding and π-stacking forces as additional factors that 
promote lipoplex formation.72 Upon incorporation in DOPE 
liposomes (6/DOPE molar ratio 1/9) the anionic nucleolipid 
diC16-3’-T 6 (Table 1) bound DNA at a Ca2+ concentration of 1 
mM;73 the low Ca2+ concentration in the cell (1 M) would 
therefore contribute to the release of DNA from the lipoplex. 
HEK293 cells could be transfected with pE-GFP (Green 
Fluorescent Protein) at a relatively low toxicity. There appears 
to be no example of nucleosides attached to cholesterol or in a 
gemini, as discussed below for other head groups.72  
The combination of anionic nucleolipids with Ca2+ is a way 
to evade the toxicity associated with cationic lipids. Another 
approach in which the use of cations is minimized, at least for 
cell-lipoplex recognition, is cell surface engineering using the 
SnapFect system.74 Here the cells to be transfected are 
immobilized and first exposed to mixed DOTAP (2b)/POPC (1c) 
liposomes containing the ketone-lipid 7a (Table 1C), which 
fuse with the cell membrane to give the so-called ketone-cell, 
with ketone functionalities at the surface. These can then react 
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with the lipoplexes, based on 2b/1c but also containing the 
oxyamine-lipid 7b, which reacts (clicks) with the ketone 7a to 
give the oxime 7c, promoting the interaction between target 
cell and lipoplex as well as subsequent transfection. The 
principle has been demonstrated for transfection of 3T3 
fibroblast cells by GFP with high cell viability. 
The steroid cholesterol (HO-Chol, shown in Figure 3 along 
with some other alternative hydrophobic tails) and its esters 
are the most important (30 %) components of animal cell 
membranes, increasing the molecular packing by the 
hydrophobic interaction with the phospholipids’ alkyl chains, 
while maintaining the membrane’s fluidity and integrity. As 
expected on the basis of its compatibility with the cell 
membrane, it is possible to replace the two alkyl tails in a 
surfactant by a single Chol moiety, leading to vectors such as 
3β-[N-(N’,N’-dimethylaminoethane)carbamoyl] cholesterol 
(DC-Chol, 8a, Figure 3); with DOPE as a helper lipid, the CAT 
plasmid was incorporated and expressed in a variety of cells of 
mammalian origin.75 Cationic derivatives of Chol proved, 
however, also to be protein kinase C (PKC) inhibitors,76 which 
is detrimental to the physiological integrity of a cell; 
derivatives with a quaternary nitrogen head group were much 
stronger inhibitors than tertiary ones.77 
 
 
 
 
 
 
 
Figure 3. Alternative hydrophobic tails. 
 
2.2. Multivalent cationic lipids 
Most cationic lipids form polycationic aggregates 
(liposomes) of which the cationic groups can associate with the 
phosphate groups of the nucleic acids and thus neutralize their 
negative charges. In this reaction (Equation 1, step 1 in Figure 
2) the natural cationic counterions of the nucleic acid are 
exchanged for the cationic groups of the lipid aggregate.78 The 
lipoplex should preferentially be formed with an excess of 
positive charge, i.e. n for N+ (cationic lipid) > n in P-n
n- 
(polynucleotide), so that it is attracted to the negatively 
charged cell surface; this means that the nominal charge ratio, 
indicated as N/P (because the positive charge in the lipid is 
typically on N, and the negative charge in the nucleotide on P), 
has to be > 1. 
 
 (Eq. 1) 
 
An important factor in the efficiency of the ion exchange 
reaction (Equation 1) that leads to the lipoplex is the 
multivalency effect,79 by which multiple binding interactions 
can give rise to binding constants much higher than the sum of 
individual binding interactions. A single polynucleotide 
molecule has multiple negative charges, which can interact 
with multiple cationic charges on the surface of a liposome; to 
incorporate multiple cationic charges into a lipid molecule 
would therefore greatly enhance its DNA condensation ability. 
Examples of linear and cyclic multicationic groups are shown in 
Figure 4. For example, the combination of the pseudoglyceryl 
scaffold with carboxyspermine Sp(CO) gives 2,3-dioleyloxy-N-
[2(spermine-carboxamido)ethyl]-N,N-dimethyl-1-propanamine 
(DOSPA, 9, Figure 4), an important component in the 
commercially available Lipofectamine.80 5-carboxy-
spermylglycine dioctadecylamide (DOGS, 10, Figure 4),81 which 
does not contain glycerol as a linker, is effective with saturated 
alkyl tails. The effect of (partial) replacement of the H atoms in 
the alkyl tails by fluorines has also been explored, as the 
resulting fluorocarbon tails are even more hydrophobic than 
their hydrocarbon analogues;82 indeed fluorinated analogues 
of 10,83,89 but also of DOTMA 2a85 and DOSPA 986 are also 
active in transfection, often with much reduced toxicity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Multivalent cationic lipids. 
 
The multivalent lipid 11 (MVL5, Figure 4) contains an 
additional propane-ammonium moiety in its head group, and 
has its hydrophobic tails attached to a 3,4-dioleyloxybenzoic 
acid scaffold; with DOPC 1b (Table 1) as a helper lipid, it was 
more efficient in the transfection of mouse fibroblast L cells 
than DOTAP.87 It was also active in transfection of siRNA in 
knockdown of luciferase in mouse fibroblast L cells.88 
Interestingly, like for DOTAP 2a, a larger amount of MVL5 11 
isrequired for the transfection of siRNA than for DNA, due to 
the larger retention of counterions by plasmid DNA in the ion 
exchange reaction (Equation 1). It should be mentioned here 
that cationic surfactants with long linear polyamine chains as 
head groups can have a low gene delivery efficiency because, 
as revealed by molecular dynamics simulations, they can 
undergo self-folding.89 For this reason, the cyclic polyamine 
cyclen has recently emerged as an alternative multivalent head 
group,90 and its pseudoglyceryl derivatives 1291 are shown 
here (Figure 4). As the mono-oleyl derivative 12a was less 
active and more toxic than the cholesterol analogue 12b, 
further examples of combinations of cyclens with other 
structural moieties will be discussed in the relevant sections.  
 
2.3. Bola-amphiphiles  
Another direction in the development of lipid-based 
vectors is the use of bipolar lipids, or bolaamphiphiles 
(bolas).92,93 Bolas carry two polar groups on opposite sides of 
the hydrophobic chain; they can span the biological membrane 
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as a single molecule, and form monolayer membranes by 
themselves. Bolas with two different polar groups can be 
synthesized, for example with a neutral carbohydrate on one 
end, and a cationic Sp on the other, as in the early example 
GalSper 13a (Figure 5),94 and the more recent Orn-16-L 13b,95 
which can generate asymmetric membranes (e.g. in the form 
of vesicles) having positively charged inner and neutral outer 
surfaces. In such cases the inner shell surface binds the DNA or 
RNA molecule, while the lack of positively charged groups on 
the outside minimizes the toxicity. The neutral outer 
membrane surface is utilized for exposure of biological signals 
for specific targeting. The galactose residue on the outer 
surface in 13 is expected to improve the transfection efficiency 
by recognition of the asialo-glycoprotein (ASGP) receptor in 
human HepG2 or murine BNL-CL2 hepatocytes and thereby 
promote receptor-mediated endocytosis. In spite of this 
advantage, the bolas alone showed relatively weak 
transfection efficiency. For 13b, efficiencies in the transfection 
of Hela, COS-7 and HepG2 with luciferase that were 
comparable to PEI were only achieved at N/P 10 in the 
presence of DOPE ( = 0.5). In the bolas 14 with galactose and 
cationic head groups based on amino acids, fluorocarbon 
segments were inserted in the hydrophobic parts to varying 
extents.96 For the transfection activity of COS-7 cells with CAT, 
Lys was preferred to His, and the optimum degree of 
fluorination is important, since the Lys-containing 14a and, to 
a lower extent, 14b were active, whereas their His analogue 
14c and the more highly and the less fluorinated analogues 
(structures not shown) were not.97 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Bola-amphiphiles for transfection.  
 
In another group of asymmetric bolas, the cell-penetrating 
peptide R8 (8 Arg residues) was combined with the tumor-
targeting sequence RGD by means of a 12-amino-dodecanoic 
acid linker (15a, Figure 6),98 a 6-amino-hexanoic acid linker 
(15b), or no linker at all. They were compared to free R8 and 
PEI in the transfection of HeLa and 293T cells with luciferase. 
All peptides gave far better cell viability results (70-80 %) for 
both cell types than PEI (11-12 %). The transfection efficiency 
of 15 increased with the length of the spacer, and that of 15a 
was for a w/w ratio of 25 almost the same as that of PEI. In the 
series of symmetric bola 26 with dendritic peptide head groups  
based on Lysine residues,99 the hydrophobic cores are 
relatively small, which is thought to be a disadvantage for 
insertion into the biological membrane. Of the various 
dendrons investigated (G1 with 1, G2 with 3, and G3 with 5 
Lys) the G2 head group was found to be the best one; it is only 
mildly basic, since all amino groups of Lys are used in amide 
bond formation, and the dominant free amino acid residue is 
the imidazole group of the His component. The bolas 16 are 
about 2 orders of magnitude less toxic than their monomeric 
counterpart (the peptide dendron with just a lauroyl (C12) 
tail). Relatively large N/P ratios (up to 45) were needed to 
effect GFP gene silencing in NIH 3T3 cells, and the non-
hydrophobic PEG analogue 16b was completely inactive. The 
fluorinated analogue 16c was remarkably effective in siRNA 
complexation, gene silencing, and serum stability. Compounds 
16 also feature disulfide groups which are expected to be 
reductively split in the reducing environment of the cell (see 
section 2.4), effectively detaching the cationic dendrons from 
the hydrophobic core, by which the bola aggregate should be 
disassembled, leading to release of the nucleotide.  
The conceptually simple bola 17 (Figure 5), with a single 
neutral hydroxyl group at one end and a trimethylammonium 
group on the other, did not form vesicles; combined with 
DOTAP (17/2b ratio 1:5), it was equally active in the 
transfection of HEK293 cells with GFP as 2b alone, but with 
reduced cytotoxicity.100 The symmetric multivalent bola 18 
transfected HEK293, HepG2, NiH3T3, and HeLA, and 4T1 cells 
with luciferase (N/P 8, no helper lipid), with high cell viability 
(80-90 %).101 Compound C6C22C6 19, a gemini (see section 3) 
with an extremely long spacer, had an activity comparable to 
that of Lipo2000* in transfection of COS-7 cells by GFP and 
luciferase with DOPE as the helper lipid (0.2 <  < 0.5).102 
 
2.4. Bioreducible and/or dimerizable lipids 
Amphiphilic molecules that contain thiol groups in the 
hydrophobic part can be oxidatively linked by disulfide 
formation to give a bola as in the example of 16 in the previous 
section; this bolaamphiphile can then be decomposed into the 
2 monomers by splitting of the disulfide bond in the more 
reductive environment in the cell. This principle can also be 
applied to thiol groups in the polar head groups of amphiphilic 
molecules, where oxidation (Figure 6A) would lead to a 
disulfide-containing gemini (see next section 3.1), which could 
be split into thiol-containing monomers in the cell. In this 
review, most dimerizable surfactants will be treated as 
bioreducible geminis in section 3 according to the type of head 
group and/or aliphatic tail involved; a few representative 
examples will be discussed here.  
Investigations of a series of cationic Orn-Cys-alkylamine 
surfactants 20 (Figure 6B)103 revealed that their oxidative 
dimerization was accelerated in the presence of DNA; the DNA 
molecule thus served as a template, binding the cationic 
molecules by ion-exchange, which then leads to the formation 
of gemini surfactants, according to the reactions given in 
Equation 1 and Figure 6A, respectively. The activity in 
transfection of luciferase in 3T3 murine fibroblasts, BNL CL.2 
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murine hepatocytes, and HeLa cells increased in the order 20a 
< 20b < 20c, but was less than that of TransfectamTM by an 
order of magnitude. The activity of transfection of mouse 
fibroblast L-cells with luciferase by disulfide analogues of the 
multivalent cationic lipid MVL5 11, the CMVL series 21, were 
studied in mixed liposomes with DOPC.104 With 40 % DOPC, 
the best compounds 21d and 21c had activities comparable to 
that of Lipofectamine 2000TM, but with much better cell 
viability; the activity decreased with the number of positive 
charges in the head group in the order 21d > 21c > 21b > 21a.  
 
 
 
 
 
 
 
 
 
 
Figure 6. A) Oxidative dimerization of an amphiphilic thiol into 
a disulfide gemini surfactant. B) Reducible transfection agents. 
3. Gemini surfactants 
 
3.1. Introduction 
Gemini surfactants are a relatively young subfamily of 
amphiphilic molecules containing two head groups and two 
aliphatic tails which are linked by a spacer between the head 
groups, or between the linker region connecting the heads and 
the tails (Figure 7).105-108 Their critical aggregate concentration 
is 103-fold lower compared to the corresponding monovalent 
compounds (i.e. the classical surfactants with a single chain 
and a single head group), which reduces the amount of 
material required for e.g. solubilization and makes them 
interesting compounds for various applications,109 in particular 
biomedical ones,110-113 including transfection.52 The basic 
structure of geminis with their 2 head groups offers 
opportunities to take advantage of the multivalency effect (see 
section 2.2). 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Gemini: A, Gemini star constellation, arbitrarily 
connected; B and C, general structure of a cationic gemini, 
connected at the head (B) or in the linker region (C); D, natural 
gemini (cardiolipin, 22a) and cationic cardiolipin analogue 22b. 
If the area of the combined head groups is not larger than 
the cross section of the two tails (P ≈ 1), gemini surfactant 
molecules will aggregate into bilayers, and be compatible with 
the plasma membrane. An interesting difference in the 
behaviour of cationic surfactants in vesicle bilayers of anionic 
phospholipids is that all the anionic charge of the vesicle can 
be neutralized by addition of a classical cationic surfactant 
when the bilayer is in its ‘liquid’ state, and half of it when it is 
in the ‘solid’ state, whereas cationic gemini surfactants 
neutralize only half of the anionic charge, irrespective of the 
state of the bilayer.114 This difference is ascribed to the much 
lower propensity of gemini surfactants for ‘flip-flop’, which 
makes them much more similar to phospholipids than classical 
surfactants.111  
The spacer in gemini surfactants opens great possibilities 
for variation, in addition to variations of the head groups and 
tails in conventional surfactants.107 It can be anything from a 2- 
to 10-carbon or longer aliphatic linker,93 or a rather polar 
polyamine.115 In some gemini surfactants the spacer is so 
dominantly aliphatic that they should practically be considered 
bola-amphiphiles (e.g. compound 19 in section 2.3).92,93 The 
head groups can vary from anionic sulfate via non-ionic sugars 
to cationic ammonium moieties, either chiral or achiral.116-118 
Geminis that are asymmetric due to the presence of a peptide 
spacer have been dubbed geminoid or gemini-like 
surfactants119 and will be discussed in section 4. Interestingly, 
a biological gemini phospholipid is known, cardiolipin (22a, 
Figure 7D), which is located in the inner mitochondrial 
membrane and binds protons as well as cationic mitochondrial 
membrane proteins, such as the electron transfer protein 
cytochrome c.120 A cationic analogue of this natural lipid, 22b, 
with saturated alkyl tails connected through ether bonds,121 
was proved to be effective in siRNA therapy against a number 
of tumors.122 
 
3.2. Quaternary Ammonium Geminis 
The classical cationic gemini surfactant m-s-m106 has two 
quaternary ammonium head groups, linked by a spacer of s –
CH2- groups, each containing a long alkyl tail with m carbon 
atoms. In an initial study, the transfection activities (BHK cells, 
pCMV-gal) of the compounds with saturated C16 tails 23b (s 
= 2, 3, 6, Table 2) did not differ much from those of the 
unsaturated analogues 23d, with an optimum value of 6 for 
s.123 No helper lipid was required but the transfection was 
negatively affected by the presence of serum. In spite of this 
apparent limitation, 23b with s = 6 and its dodecyl analogue 
23a were successfully applied in the transfection with the gene 
for interferon  in a therapy for the connective tissue disease, 
localized scleroderma.124 Dodecyltrimethylammonium 
bromide (DTAB) and its C14- and C16-analogues, which can be 
considered to be single chain analogues of the gemini 23, have 
been used with the helper lipid DOPE (1a) liposomes in the 
transfection of L929 (mouse fibroblast) cells with CAT, but 
turned out to be much more toxic than the LipofectinTM 
standard.125 In a more recent study on transfection by 23b 
with s = 2, 3, 5, or 12 in the presence of 1a, the optimum 
spacer length was much lower (s = 2 or 3).126 These 
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transfection studies were carried out in vitro with HEK293T, 
HeLa, CHO, U343, and H460 cells. The combination 16-2-16 
(23b)/1a was found to be the most efficient mixture for 
transfection, even in the presence of serum, and > 2 times 
better than Lipofectamine 2000TM. 
 
Table 2. Quaternary ammonium geminis with alkyl spacer. 
 
 
 
Apolar tail, Example 
a-d, R3 = R4 = a, lauryl; b, palmityl; c, 
stearyl; d, oleyl;  
e-g, s = 3, R3 = phytanyl (Fig. 4); e, R4 = 
lauryl; f, R4 = palmityl; g, R4 = stearyl 
23 
R1 = R2 = Me,  X = Br 
24, R1 = Me,  X = Cl R2 = R3 = R4  = oleyl; a, s = 3; b, s = 6 
25, R1 = R2 = Me, X = 
Br, s = 2 
 R3= R4 =   n = 9 (a); 11 
(b); 13 (c) 
26, R1 = R2 = Me, X = 
Br, s = 3, 4, 5, 6, 12 
27, (CH2)s = 2 Me 
R3=  
R4 =   
n = 11 (a);      
13 (b);       
15 (c) 
28, R1 = R2 = Me, X = 
Br; 29, (CH2)s = 2 Me 
R3 = R4 = (CH2)2OChol s = 3, 4, 5, 
6, 12 
30, R1 = Me, R2 = 
CH2CH2OH, X = Br; 
31, (CH2)s = 2 Me 
R3 = R4 = (CH2)2OChol s = 3, 4, 5, 
6, 12 
32, R1 = R2 = Me, X = 
Br 
R3 = R4 = (CH2)2OToc s = 3, 4, 5, 
6, 8, 12 
 
The related tetraalkyl diammonium surfactants with spacer 
length s = 3 (24a) and s = 6 (24b) and Cl- counterions, which 
can be considered to be gemini analogues of dioctadecyl-
diammoniumchloride (DODAC), were tested for their efficiency 
in the transfection of baby hamster kidney (BHK) cells with 
luciferase.127 At lipid-DNA ratios higher than 2, 24b was more 
active than DODAC, both in the presence and absence of the 
helper lipid DOPE; 24a could only be tested without DOPE but 
was the least active at all ratios. All representatives of a series 
of quaternary ammonium geminis, 25, with ester links in the 
long tails, were more efficient in the transfection of human 
rhabdomyosarcoma cell line RD-4 with pEGFP-C1 than the 
commercial GenePORTER transfection agent,128 with the best 
results for n = 11 in the presence of DOPE ( = 0.33); the 
compound with n = 13 even showed some activity, albeit much 
reduced, in the absence of the helper lipid. Another variation 
in the long tail is the incorporation of aromatic moieties129 like 
in the gemini 26 and its conventional analogue 27. In the 
transfection of HeLa cells by GFP with helper lipid DOPE, the 
compounds with C16 tails (26c, 27c) were not very active; for 
the other compounds, there appeared to be hardly an 
advantage of the gemini structure, with the highest efficiency 
found for 26a (s = 3, 4, 5), 26b (s = 5), and 27a. 
Geminis with Chol as the hydrophobic part have also been 
studied. For the series of compounds 28 (Table 2)130 the best 
activity was found for the compound with a s=5 spacer, which, 
when formulated with DOPE, gave the best transfection 
efficiencies in HeLa and U373 cells. The efficiencies of the 
gemini surfactants 28 were better than those of the 
corresponding monovalent lipid 29 with DOPE. The 
hydroxyethyl Chol geminis 30 were all more effective in the 
transfection of HeLa cells with GFP than the monomer 31,131 
and the analogue with s = 5 was most effective, at  = 0.33 and 
N/P 0.25 (0.5 in the presence of serum). Geminis with 
tocopherol (Figure 3) as the hydrophobic part 32 have also 
been prepared.132,133 The analogue with the shortest spacer, s 
= 3, was the best and even more efficient than Lipofectamine 
2000 in the downregulation of GFP with RNAi in HEK293, HeLa, 
and Caco-2 cells, at  = 0.25 and 1.5 < N/P <2.5, and without 
significant loss of cell viability;132 it was also the best in the 
transfection of Caco-2, HeLa, U251, HepG2, COS-7, BT-474, 
A549, CHO, and HEK293T cells with GFP at  = 0.25 and N/P 
0.75.133 
Of a new set of derivatives of dimeric surfactants (Table 3) 
having aza- (m-5N-m, 33a; m-7N-m, 33b; m-8N-m, 34) and 
imino- (m-7NH-m, 35) substituted spacer groups, the activities 
of the C12-analogues were studied, and 12-7NH-12 (35a) was 
found to be comparable to Lipofectamine PlusTM in the 
transfection of COS-7 cells with luciferase, albeit at the cost of 
a slightly higher toxicity.134,135 Compared to 23, the interest of 
35 is in the protonable amine at the centre of the -7N- spacer, 
and 35a-d were therefore compared to analogues of 23 with a 
spacer of the same length, but without the amine (23a-d with s 
= 7).136 Indeed the size of the aggregates of 35a-d was pH 
dependent, with smaller aggregates at higher pH, whereas 
those of 23a-c (s = 7) were pH-invariant. In the transfection of 
murine PAM 212 keratinocytes with luciferase, the activity 
increased going from 23 (s = 7) via 23 (s = 3) to 35, which came 
closest to Lipofectamine PlusTM; within each group, the activity 
increased in the order m = 12 < 16 < 18.  
 
Table 3. Quaternary ammonium geminis with other spacers. 
 Apolar tail, Example  
R1 = R2 = (CH2)m-1CH3 
# R1 = R2 (m) 
X = Br, n = 2, Y = -N(Me)- 33a 12 
X = Br, n = 3, Y = -N(Me)- 33b 12 
X= Br, n= 2, Y= -(Me)N(CH2)2N(Me)- 34  12 
X = Br, n = 3, Y = -NH- 35  
# R1 (m) R2 (m) 35a 12 
35e phy 12 35b 16 
35f phy 16 35c 18 
35g phy 18 35d oleyl 
X = Cl, n = 3, Y = LysGly-N 46(Lys-Gly) a, 12; b, 16; c, oleyl 
X = Br, n = 1, Y = -{CH2OCH2}k-      37a-c, k = 1, 2, 3 16 
X = Br, n = 2, Y = -S-S- 38-S-S-38 16 
X = Br, n = 1, Y =  
 
39 12 
X = Br, n = 1, Y = 2 Ph 40 12 
X = Br, n = 1, Y = -{CH2OCH2}k-      
 
41a-d, k = 
1, 2, 3, 5 
(CH2)2OChol 
X = Br, n =1, Y = -(CH2)5- 42a (CH2)2SSChol 
X = Br, n = 1, Y =  
 
42b (CH2)2SSChol 
X = Br, n = 1, Y = -{CH2OCH2}-      42c (CH2)2SSChol 
X = Br,  
n = 5 or 10, Y = 
  
43 (CH2)2OChol 
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Because of the tendency of surfactants with phytanyl tails 
(Phy, Figure 3) to give fusogenic hexagonal lipid packings,137 it 
was considered of interest to investigate gemini surfactants of 
type 23 with n = 3 and different alkyl tails, of which one is a 
phytanyl (23e-g, Table 2).138 In the synthesis of these 
compounds, the stereochemistry of one of the centres in the 
phytanyl bromide building block is not controlled, which 
implies that, due to the presence of other chiral centres in the 
phytanyl chain, 23e-g are prepared and studied as mixtures of 
diastereoisomers. Compared to the analogues 23a-c with n = 
3, the hydrophobic volume in 23e-g was much increased, 
causing a shift in the packing parameter P from values around 
0.35, giving cylindrical micelles, to approx. 0.55, more 
consistent with vesicles. The asymmetric geminis 23e-g were 
more efficient than 16-3-16 (23b, n = 3) in the transfection of 
ovarian cancer cells OVCAR-3 with GFP, but not as active as 
Lipofectamine 2000TM. In a subsequent study, these results 
were compared to those for the phytanyl analogues of 35a, 
viz. 35d-f;139 this series turned out not to transfect OVCAR-3 
cells, in spite of the aforementioned activity of 35a in COS-7134 
and PAM 212136 cells. 
The 12-7N-12 cationic gemini 35a was appended at the 
central N with amino acids (Gly, Lys) and dipeptides (Lys-Gly, 
Lys-Lys), for which the structure of 12-7N(Lys-Gly)-12 is given 
as an example (36a(Lys-Gly), Table 3).140 In the transfection of 
COS-7 cells with interferon  and DOPE as a helper lipid, 
optimum expression was reached after 72 h, with efficiencies 
decreasing in the order 36a(Gly) > 36a(Lys-Gly) > 36a(Lys) > 
Lipofectamin PlusTM > 36a(Lys-Lys) ≈ 35a. In the transfection of 
PAM 212 (murine keratinocytes) the activities of the 36a 
analogues were quite similar and much better than that of 35a 
although much worse than that of Lipofectamin PlusTM; this 
standard performed very poorly with Sf 1Ep cottontail rabbit 
epithelial cells, where 36a(Gly) was the most efficient, 
followed by 36a(Lys-Gly) > 35a > 36a(Lys) > Lipofectamin 
PlusTM > 36a(Lys-Lys). The differences in efficiency of 35 and 
36a for various epithelial cell types were ascribed to 
differences in the amount of proteoglycan on the cell surfaces. 
The presence of an amino acid/peptide in 36a is expected to 
soften the electrostatic interactions between lipoplex and 
proteoglycan by additional van der Waals and H-bond 
interactions, as compared to 35a, and the larger hydrophilic 
head group results in higher biocompatibility and (although 
not investigated) reduced toxicity. The cellular uptake of 
lipoplexes of 35a and 36(Lys-Gly) was not affected by the 
attempted selective inhibition of clathrin-mediated and 
caveolae-mediated endocytosis with respectively genistein and 
chlorpromazine, but much reduced by methyl--cyclodextrin, 
which affects both pathways.141 The transfection with 
interferon /GFP was affected by inhibition of the caveolae-
mediated pathway for 35a but not for 36a(Lys-Gly), whereas 
inhibition of the clathrin-mediated pathway enhanced the 
transfection by 35a while slightly reducing that by 36a(Lys-
Gly). It is proposed that with both surfactants, endosomal 
escape from caveolae is possible, but that 36a(Lys-Gly) can 
escape from clathrin-coated endosomes by a proton-sponge 
effect, due to the buffering by the Lys residue, whereas 35a  
can not. More recently analogues of 36(Lys-Gly)a-c with 
varying tail lengths were compared, with the best result for 
the C16-derivative 36b with DOPE at N/P = 2.5. 142 
The oxyethylene linker in 37143 is reminiscent of the 
aforementioned (section 2.1) neutral but hydrophilic PEG 
moieties, which can be incorporated in cationic lipid 
aggregates to prevent their aggregation with anionic 
biomolecules. In the transfection of HEK293T cells by pEGFP-
C3, 37c was most efficient ( 0.7), and better than the 
Lipofectamin 2000TM standard, both in the presence and 
absence of serum, followed by 37a and 37b; 37b also gave the 
poorest cell viability results, although better than the 
standard, while 37a was the best in this respect. In a number 
of other cell types, viz. HeLa, CaCo-2 (Human epithelial 
colorectal adenocarcinoma), Hep3B and MDA-MB231 cells, 
37a was always the best, and 37b the poorest transfection 
agent. The analogue of 23b (16-6-16) with 2 S atoms in the 6 
atom-spacer, 38-S-S-38, is an example of the aforementioned 
(section 2.4) disulfide dimers, which can be reduced in the 
reductive environment of the cell by the thiol compound 
glutathione, according to the reaction in Figure 6A, in this case 
giving the monomeric, non-gemini surfactant 38-SH (Table 
3).144 It was demonstrated that glutathione can indeed split 
the S-S bond of 38-S-S-38 molecules in monolayers at the air-
water surface, but reduction in the presence of DNA was much 
slower, resulting in a disappointing transfection activity. It is 
concluded that the S-S bond is not reduced effectively if it is in 
the hydrophobic part of the surfactant molecule. The 
transfection of COS-7 cells by GFP by the with m-phenylene 
gemini 39 with DOPE (0.2 or 0.5) was comparable to that of 
Lipo2000*; the corresponding monomer 40 was less effective 
at low , and more toxic at low N/P.145 
The series 41a-d with oxyethylene spacers of varying 
length and the Chol linked by an O atom were also 
investigated (Table 3).146 All oxyethylene gemini surfactants 
were better than the monomer ‘half-gemini’ 31 in transfecting 
HeLa cells with GFP, with the best results for 41a (n = 1) and 
the worst for 41d (n = 5). A remarkable observation was that 
the transfection by 31 was strongly affected by the addition of 
10 % serum, whereas that by 41a-d was not. The analogues 
42a-c (Table 3) in which the Chol is not attached by an O but 
by a reducible disulfide bridge were tested for transfection of 
Hela and HT1080 cells by GFP with DOPE, with practically no 
toxicity.147 The aromatic linker in 42b proved to be a 
disadvantage in this case, since the order of transfection 
efficiency was 42a ≈ 42c > 42b for HeLa cells, and 42a > 42c > 
42b for HT1080 cells.  
In compounds 43, the quaternary ammonium groups were 
linked by a redox-active ferrocenyl spacer. In the transfection 
of Caco-2, HEK293T, and HeLa cells with GFP, the compounds 
with the shorter (n = 5) were more active than those with the 
longer (n = 10) spacer, but less active than the analogues with 
just one quaternary ammonium/Chol group attached to the 
ferrocenyl.148 As in earlier studies on ferrocenyl-containing 
cationic lipids, the activity was abolished when the ferrocenyl 
group was oxidized,149 but for 43 it could be reinstated upon 
reduction of the lipoplex with ascorbic acid. 
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3.3. Carbohydrate Geminis 
Carbohydrates can be combined with lipids to give 
glycolipids, and given a positive charge to act as transfectants. 
This is of interest because many cell types have receptors for 
carbohydrate moieties,150 and the high level of hydration of 
carbohydrates possibly weakens the binding of the cationic 
ammonium groups to the DNA, thus facilitating its release. The 
series 44 (Figure 8), with the open-chain galactose-derived 
carbohydrate directly linked to the ammonium, showed 
transfection in CHO, COS-1, MCF-7 and A549 (Human lung 
adenocarcinoma epithelial) cells, in particular with the C14 
(44a) and C16 (44b) tails, while the related compound 45 with 
a longer spacer between head group and alkyl tail was not 
biologically active.151 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Carbohydrate classical and gemini transfectants.  
 
A series of geminis based on reduced glucose in which the 
spacer and alkyl tails were varied, was synthesized93 and 
tested for biological activity both in vitro and in vivo.152 Of the 
series with saturated tails 46a-h, the surfactants with 
hexadecyl tails 46e-f appeared to have the highest transfection 
efficiencies, comparable to Lipofectamine Plus2000TM, for β-
galactosidase in CHO-cells without a helper lipid, and the 
activity was slightly higher for the derivatives with s = 4 than 
for s = 6. The polar amine groups are procationic, and have an 
influence on each other, resulting in e.g. pKa values of 8.3 and 
5.8 for 46i153 and pH-dependence of its aggregation behaviour 
and interaction with DNA.53 In a subsequent study, the glucose 
and mannose oleyl surfactants with alkyl (s = 6) spacers (46i 
and 46j) were compared to their counterparts with 
oxyethylene spacers (47a and 47c) and their amide analogue 
47b.154 In the transfection of CHO-K1 cells with GFP, the 
activity decreased in the order 47a > 47c > 46j > 46i, with 
activity of 46i comparable to that of the standard 
Lipofectamine 2000TM, while the amide 47b showed no 
activity; only 47c was less toxic than the standard. 
 
3.4. Geminis with Multivalent Head Groups  
The naturally occurring polyamine Sp (Figure 4) has been 
symmetrically appended with 2 Chol residues to give the 
compounds 48 (Figure 9).155 Compound 48a and its analogue 
featuring S-S bonds between the Chol and Sp moieties, 48e, 
were more active than the standard Lipofectamine 2000TM in 
the transfection of HEK293 cells by pEGFP-C2 plasmid with 
DOPE ( = 0.5) at N/P ratios >4.156 The activity of 48e was 
slightly lower than that of 48a and was abolished by 
extracellular glutathione, presumably due to reduction of the 
S-S bond, which would result in detachment of the cationic Sp 
head group of 48e from the hydrophobic Chol part. Other 
variations in the connection between Sp and Chol had subtle 
effects, with the best results for 48b (N/P 6) and 48d (N/P 8) in 
transfection of HEK293 cells as measured by the percentage of 
fluorescent cells resp. mean fluorescence intensity, and for 48c 
(N/P 8) in GFP silencing in BHK IR-780 cells.157 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Geminis with multivalent head groups 
 
At N/P < 4 the cyclen-based gemini surfactants 49-50158 (Figure 
9) were less toxic than Lipofectamine 2000TM in HEK293 cells. 
Their transfection activity was tested with luciferase (pGL-3) 
and eGFP (pEGFP-N1) plasmid DNA in HEK293 cells in the 
presence of the helper lipid DOPE. The amides 50 and the HO-
Chol ester 49f were relatively inactive, and although for the 
other esters 49 the unsaturated 49d was slightly more active 
than its saturated analogue 49e, the highest activities were 
observed for the relatively short-chain (C12 and C14) 
derivatives 49a and 49b; of the reverse esters 51, the myristoyl 
analogue 51b was the most active. Of the single-chain 
analogues 52, 52a was internalized in spite of the relatively 
large size of its lipoplex, but nonetheless resulted in much 
poorer transfection than displayed by its gemini analogue 49a. 
Bioreducible geminis with 2 cyclen head groups, an S-S linker, 
and hydrophobic tails connected as amides (53) or esters (54) 
were also investigated in combination with DOPE ( = 0.33), 
and compared with a non-dimerizable single-chain analogue 
55.159 All compounds 53-55 were less toxic than Lipofectamine 
2000TM up to an N/P ratio of 8; the HO-Chol ester 54d was 
least toxic but also had the weakest interaction with DNA and 
was not further tested for biological activity. In the 
transfection of HEK293 cells with luciferase, the amides 53 
were more active than the esters 54, with the activity 
decreasing in the order 53b (oleyl) > 53a (lauryl) > 53c (linoleyl) 
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and 54b > 54a ≈ 54c. The activity of the best compound in this 
group, 53b, was close to that of Lipofectamine 2000TM. 
Because of the generally lower activities of these compounds, 
the activity of the non-gemini 55 was only approx. 1 order of 
magnitude lower than that of its closest gemini analogue 53a. 
Quite recently, another cyclic multivalent head group, 
triazacyclododecane [12]ane-N3, has been linked by a triazole 
to a tetraphenylethylene platform with varying alkyl tails to 
give 56.160 The transfection of HepG2 cells by luciferase and 
DOPE decreased in the order 56b > 56a >> 56d > 56c and was 
in all cases less efficient than that by Lipo2000. 
 
3.5. Geminis with Dispersed Charges 
A strategy to overcome the toxicity problems of 
transfectants is to spread the positive charge of the cationic 
head. An early example is to use the amidine group like in 
diC14-amidine (Vectamidine, 57, Figure 10)161, which with PE 
as a helper lipid was active in the transfection of CHO and 
K562 cells with CAT. The guanidinium group in the amino acid 
arginine is a biological cationic group with dispersed charge; it 
has been coupled to DOTMA 2a, yielding Arg-DOTMA 
derivative 58,162 which gave good transfection of V79 (Chinese 
hamster lung) and HT29 cells. The positive charge can also be 
delocalized in a heterocyclic ring like pyridinium, as in the 
SAINT-2 (59, Figure 10, commercialized with DOPE as SAINT, 
Synthetic Amphiphile INTeraction)163 and Sunfish 60164 lipids. 
The pyridinium surfactants generally have lower cytotoxicity 
than lipids with quaternized amine head groups, as shown also 
in a direct comparison of the pseudoglyceryl compound 3 
(DOTAP) with its analogue with the quaternary ammonium 
group substituted by 2,4,6-trimethylpyridinium 61.165 
Imidazolinium and imidazolium rings are other examples of 
heterocyclic rings in which positive charge can be delocalized. 
The latter was tested in the lipophoshoramidate framework 
(Figure 10),166 where the methylimidazolium compounds 62c 
and 62d were found to be more efficient and less toxic than 
the guanidinium compounds 62a and 62b. The developments 
of the lipophosphonates and lipophosphoramidates have been 
reviewed elsewhere.167 
 
 
 
 
 
 
 
 
 
Figure 10. Transfection agents with dispersed positive charge. 
 
For pyridinium-containing geminis 63 (Table 4) related to 
59, with 4 alkyl tails, the highest transfection efficiencies were 
found for a pentamethylene spacer (63, s = 3).163 In contrast to 
the transfection results of other gemini surfactants discussed 
above and below, pyridinium geminis were found to be less 
effective than their monomeric counterparts. For another 
group of geminis 64 the optimal spacer length for transfection 
of MCF-7 cells by luciferase with HO-Chol as helper lipid ( = 
0.5, N/P = 2) was found to be a dimethylene spacer (s = 0), 
which was comparable to DOTAP; remarkably the transfection 
increased again at spacer lengths > s = 6.165 Insertion of 
nitrogens in the spacer of pyridinium geminis with varying 
nitrogen content (65 vs. 66a, which has Sp at the core of its 
spacer) and linker length (65a-c) did not improve the 
transfection of NCI-H23 (lung carcinoma) cells by luciferase 
with HO-Chol as helper lipid ( = 0.5, N/P = 2) compared to 64 
(m = 0 or 8), and showed a similar bimodal dependence on 
spacer length: 66a > 65a > 65b > 65c (virtually no activity).168 
Of derivatives of 66 where the nitrogens in the centre of the 
spacer had been amidated (66b, c) or alkylated (66d), only the 
latter was more active than LipofectamineTM, this time with a 
preference for DOPE ( = 0.5) as a helper lipid. Appending the 
central N in 64b with another amphiphilic pyridinium led to 
the unique ‘sesquigemini’ amphiphile 67, which was less active 
than 66d and LipofectamineTM, but was relatively indifferent to 
the presence or choice of helper lipid. Incorporation of a 
reducible disulfide in the spacer (68) resulted in loss of 
transfection activity, irrespective of the counterion (PF6
- or Cl-) 
used.  
Table 4. Headgroups with dispersed charge, A) and C) 
pyridinium resp. imidazolium geminis; B) pseudogeminis. 
A 
 
 
 
R1 R2 R3 
63, X = Cl, Y = (CH2)s, R’ = C16 Me Me CHR’2 
64, X = PF6, Y = (CH2)s C14 Me Me 
65, X = PF6, Y = (CH2)nNH(CH2)m                                C14 Me Me 
65 a, m = n = 1;  b, m = n = 2; c, m = 2,  n = 3; 
66, X = PF6, Y = 
(CH2)2NR’(CH2)4NR’(CH2)2 
C14 Me Me 
66 R’ = a, H; b, myristoyl; c, palmitoyl; d, myristyl 
68, X = PF6, Y = CH2-S-S-CH2 C14 Me Me 
72, X = Cl, Y = CH2OCH2 C9-C17 Me Me 
67, Y =  
X = PF6 
 
 
C14 Me Me 
73 
73a, R = C16H33, p = 1, 2, 6, 10 
73b, R = (CH2)2(CF2)5CF3, p = 1, 2, 3, 4 
B            69, X = O; 70, X = NH 
 
 
a, m = 10;  b, m = 12;  c, m = 14 
71 
 
 
a, m = 10; b, m = 12; c, m = 14 
C 74,  Y = (CH2)n; a, n = 2 R = lauryl 
74 b, n = 0; c, n = 1;  
d, n = 3; e, n = 10 
R = 
palmityl 
75, Y = (CH2OCH2)n a, n = 1; b, n = 2; c, n = 3 R = palmityl 
 
The ‘pseudogemini’ surfactants are called this way because 
they have 2 alkyl tails but only one pyridinium head group; the 
other polar element is an ester (69) or amide (70) in the linker. 
With N/P = 2 and DOPE ( = 0.5), these compounds gave 
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transfection of NCI-H23 cells equivalent to that of 
Lipofectamine; the optimum alkyl chain length was the 
intermediate one (b) in both cases.169 The observed lower 
(virtually absent) cytotoxicity of the ester 69 compared to the 
amide 70 was tentatively ascribed to the different products 
expected to be formed by enzymic hydrolysis. For the 
pseudogemini analogue 71 in which the amide bond is 
reversed HO-Chol was a better helper lipid than DOPE, and the 
transfection activity at N/P = 2 decreased in the order 71c > 
71a > 71b, with much reduced toxicity compared to 70.170 
Following the success of oxyethylene spacers in other 
gemini systems (41,146 see section 3.2) the oxyethylene 
pyridinium geminis 72 with varying tail lengths were also 
prepared and tested.170 The transfection activity with DOPE ( 
= 0.33) at N/P = 3 increased with n, to a value for n = 16 higher 
than that found for LipofectamineTM. It was then attempted to 
take advantage of the excellent transfection efficiency of 
gemini 72 (n = 16), due to its membrane destabilization and its 
high charge/mass ratio, with the good transfection activity and 
somewhat reduced cytotoxicity of the conventional pyridinium 
surfactant 61b (a symmetric isomer of the pseudoglyceryl 
pyridinium compound 61a, see Figure 10), by studying 
mixtures of these compounds.171 The addition of 5-10 % 
gemini 72 to 61b improved the transfection of NCI-H23 cells by 
GFP with DOPE 1a as the helper lipid ( = 0.33, N/P = 3). 
Moreover, there was evidence for a change in the endocytotic 
mechanism of uptake by the cell (see section 2.2): transfection 
by 61b/1a was inhibited by 5-(N-ethyl-N-isopropyl)amiloride 
(EIPA), which interferes with macropynocytosis, whereas 
transfection by 61b/72/1a was also inhibited by genistein, 
which interferes with the caveolae pathway. Interestingly, with 
HO-Chol as the helper lipid (0.33 <  < 0.50), the incorporation 
of 72 results in suppression of endocytosis involving clathrin, 
caveolae as well as macropinocytosis, which, in view of the 
improved transfection efficiency, suggest that yet another 
uptake mechanism operates in this case, possibly temporary 
poration of the cell membrane by 72. The results for this class 
of pyridinium surfactants where the head groups are 
connected by spacers directly attached to the quaternary 
nitrogen atoms have been reviewed.172   
Another class of pyridinium geminis, 73a, with long alkyl 
tails connected to the N in the pyridinium groups which are 
linked by spacers connected to the o-position, has been known 
for some time,173 but has only recently been used in 
transfection studies,174 viz. of RD-4 cells by pEGFP-C1 with 
GenePORTERTM as a standard. The analogue of 73a with m = 2 
(spacer length 4 CH2 groups) was approximately as active as 
the standard, and only marginally improved with DOPE as as 
the helper lipid (0.33 <  < 0.67); AFM revealed that this was 
the only analogue of 73a that could condense DNA to particles 
with a diameter < 100 nm. Of the other analogues of 73a given 
in Table 4, only the one with p = 6 had some activity, and 
required DOPE ( = 0.5). The fluorinated analogues 73b all 
required DOPE ( = 0.33), and except for absence of any 
activity for p = 10, the dependence on the spacer length was 
completely different: the highest activity was observed for p = 
6 (comparable to standard, lipoplex particles < 100 nm), with 
much lower activities for p = 1 and 2.175 
The imidazolium gemini 74a showed efficient transfection 
of HEK293 and HeLa cells with GFP with negligible cytotoxicity 
up to a concentration of 10-5 M (Table 4).176 The dependence 
of the transfection of HEK293 cells by GFP with DOPE as a 
helper lipid ( = 0.2) on the spacer length was investigated for 
the analogues 74b-e with C16 instead of C12 tails,177 and 
found to decrease in the order m = 0 (74b) > 3 (74d) > 1 (74c) > 
10 (74e). In a comparison with the ammonium geminis 23b 
and 41 and the alkyl-spaced imidazolium gemini 74c, the 
oxyethylene analogue 75c was biologically the most active; all 
geminis included in this comparison outperformed the 
standard Lipofectamine 2000TM. In a subsequent study178 the 
knockdown of EGFP by the appropriate siRNA in EGFP-
expressing HEK293T cells was achieved, this time with a 
different helper lipid, i.e. mono-oleoyl glycerol.179 
 
3.6. Amino Acid and Peptide Geminis 
Amino acids and peptides coupled to lipids are also used in 
transfection,180 for example in the aforementioned Arg-
DOTMA derivative 58.162 Attachment of a stearoyl group to the 
N-terminus of the cell-penetrating peptides TAT, REV, FHV and 
R8 (stearoyl-HN-peptide-CO-NH2) improved the transfection of 
COS-7 cells with luciferase, with the best results, comparable 
to Lipofectamine, for R8.
181 Stearoyl-appended R8 gave better 
condensation of the DNA, better adsorption to the cells, and 
better delivery to the nucleus than R8 itself;
182 incorporation 
(10 %) of the lipopeptide in liposomes led to uptake through 
macropinocytosis, resulting in less lysosomal degradation than 
in the case of clathrin-mediated endocytosis.183 
The aforementioned polyamine Sp (Figure 3) can be 
symmetrically connected by amide bonds to an amino 
acid/peptide and oleic acid in two different ways (Figure 11), 
i.e. with the peptide at both terminal N, and the oleoyl at the 
central N atoms (76), and the other way around (77).115 The 
transfection of a number of cells, CHO-DG44, C2C12 (mouse 
muscle), nonadherent MOPC315 (mouse tumor), and 1321N1 
(neuronal) with luciferase by the Lys derivatives 76a and 77a 
and the peptides 76b and 77b was compared to that by 
Lipofectamine 2000TM. For all cell types, the geminis of type 77 
were more active than 76. The peptide derivative 77b was 
more active than the Lys-derivative 77a except for the C2C12 
cells where it was the other way around. The gemini 
surfactants were superior to Lipofectamine 2000TM except for 
the 1321N1 cells where they performed relatively poorly. In a 
subsequent study on analogues of 77a,182 it was found that the 
Lys head group was superior to alternative amino acids with 2 
amino groups, L-Orn, L-Dab (2,4-diaminobutyric acid), and L-
Dap (2,3-diaminopropionic acid), in the transfection of HEK293 
cells with luciferase; the D-Lys analogue appeared be both 
slightly more active and less toxic than L-Lys. Of a series of 
analogues of 77a with an oleoyl and one other tail (C6, C10, 
C14, C18, C18:1, and C18:3) those with 2 tails with 18 C atoms 
were the most active, with activity decreasing in the order C18 
> C18:1 > C18:3 for the other tail. The cyclospermin 78 showed 
a remarkable dependence on the nature of the links between 
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the Lys residues in the peptide; compound 78a with an -link 
only between the 1st and 2nd Lys was one of the most active 
compounds, whereas the analogue 78b with -links between 
all Lys residues was not active at all.52 
Peptide geminis with Cys-Ser-alkylamine at the core linked 
by an ethylene bridge between the Cys-S, which are remotely 
related to the dimerizable cationic surfactant 20,103 have also 
been investigated.52,183,184 Of a series of compounds with C16 
tails 79, the ones with head groups consisting of a single 
(di)amino acid, Dab 79a and Lys 79c were not active in the 
transfection of CHO cells with luciferase;183 for a series of 
peptide headgroups, the activity decreased in the order 
Lys

Lys 79d > (Lys)2Lys 79e > Lys-Ser 79b. The transfection of 
CHO-K1 cells with -galactosidase by 79d was improved by 
addition of either DOPE or Lipofectamine PlusTM, and even 
more by both. In a subsequent investigation, the C18:1 
analogues 80 turned out to be even more active than the C16 
compounds 79 and much more than the corresponding C12 
compounds, and the effect of the linkage,  or , was 
systematically investigated for head groups consisting of 3 Lys 
residues.184 The activity of these compounds in the 
transfection of CHO-DG44 cells without DOPE was compared 
to that of Lipofectamine PlusTM and found to decrease in the 
order 80d (,) > 80c (,) > 80b (,) > 80a (,) > 80e 
((Lys)2Lys);
52 compounds 80d and its C16 analogue as well as 
80c were more active than Lipofectamine PlusTM.199 These 
results can however not be generalized in the sense that for 
trilysine head groups all links should be , because of the 
aforementioned opposite result for the cyclospermine 78. The 
gemini character of compounds 80 is important for 
transfection, as demonstrated by the fact that compound 81, 
which is the ’half-gemini’ analogue of 80b, is not active.52 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Amino acid-based gemini surfactants. Links between 
Lys in peptides are  unless otherwise indicated. 
 
Another group of gemini surfactants based on lysine, viz. 
(R1(CO)-Lys(H)-NH)2(CH2)n 82 {Figure 11),
185 has a fatty acid 
(R1(CO) connected to the -amino group, and the carboxylic 
groups linked by diamine spacers of length n. The first report52 
on 82 referred to products that may have contained up to 10 
stereoisomers, due to the use of technical (Z/E mixture) oleic 
acid, combined with a racemization-prone synthetic protocol; 
this strategy was revised, starting from pure oleic acid.185 For 
spacer length n = 6 the hydrophobic acyl tail was varied in 
length (R1 = C8 to C18, 82d-i), and, for R1 = C18, the degree of 
unsaturation (C18:1 Z 82a and E 82b, C18:2 (Z,Z) 82c). For 
R1(CO) = oleoyl (C18:1 Z) the spacer length (n = 2–8, 82j-k, 82a) 
and the stereochemistry of the lysine building block (D-Lys, 
82o) were varied; a ‘half-gemini’ derivative 83 with a single 
oleoyl tail and head group was also prepared. In the 
transfection of HeLa cells with -galactosidase, with or without 
DOPE, the oleoyl derivative (C18:1 Z, 82a) was by far the best 
compound in this series. There was also a slight improvement 
with the change of Lys stereochemistry in 82o, such as also 
found for the aforementioned Sp derivative 78a. Without 
DOPE, the oleoyl derivative with n = 6 (82a) was far more 
active than those with n = 2-5 (82j-n) or n = 8 (82m), making 
this, along with the glycolipid 46i and the lipopeptide 80d, one 
of the most active compounds to come out of the ENGEMS 
project;52 with DOPE, there was hardly an effect of spacer 
length, except a slightly lower activity for n = 3 (82k). The 
gemini structure of 82a was essential; its ‘half-gemini’ 
analogue 83 was less active by 2 orders of magnitude.  
Related to 79 and 82 is the disulfide dimer 84 of a Lys-Cys 
peptide that is esterified at its C-terminus with oleyl-alcohol;186 
this showed no toxicity against HEK293 and HeLa cells like the 
standard Lipofectamine RNAiMAX TM, but it gave more efficient 
silencing of the protein kinase MEK1 with RNAi. The 
aggregates of 84 formed lipoplexes with siMEK1, in which the 
RNA was protected from degradation in serum, and from 
which it could be released by reduction of the S-S bond by 
dithiothreitol. In a subsequent report187 the activity of 84 was 
compared to its non-reducible analogue with a single –CH2- 
group in the place of the –S-S- functionality in 84, and with its 
non-dimerizable ’half-gemini’ analogue Lys-Ala-oleoyl in the 
downregulation of EGFR in MCF-7 and HeLa cells. The half-
gemini compound was both less active and more toxic. The 
lipoplexes of both geminis (N/P 10) were taken up in MCF-7 
cells by clathrin-mediated endocytosis. Although the uptake of 
lipoplexes of 84 was less or equally efficient in respectively 
MCF-7 and HeLa cells than that of the –CH2- analogue, the 
silencing was equally resp. more complete for 84; this effect 
was ascribed to reduction of the S-S bond upon uptake, 
resulting in more efficient release of the siRNA from the 
lysosome. The efforts in this field have been reviewed at an 
early stage52 as well as more recently.112 
Of the multivalent protonable amphiphilic peptides 
represented by general structure 85 (Figure 11), EHCO (85a) 
stood out as particularly effective, at N/P values in the range 8-
10 and without helper lipid, in the silencing of luciferase in 
U87-luc cells.188 This was explained by its hemolytic activity at 
pH 5.4, but not at 6.5 and 7.4, which indicates that it will 
selectively disrupt endosomal membranes at the pH of the 
transition to lysosomes. In a study where EHCO (85a) was 
applied to silence the hypoxia-inducible factor (HIF-1) in U87 
glioblastoma cells, it was shown by confocal laser microscopy 
that Alexa Fluor 488–labeled siRNA had indeed escaped from 
the lysosomes.189 Hemolytic activity is not the only important 
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factor for transfection activity, since CHO-GFP and HT29 were 
better transfected at N/P 12 by the histidine-free lipopeptides 
ECO (85b) and ECLn (85c), which is tentatively explained by an 
assumed tendency for the His-containing EHCO (85a) to take 
up a cylindrical shape, which would favour bilayer over non-
bilayer structures.190 In this connection it was shown that 
oxidative polymerization of the 2 thiols in ECO (85b) upon 
lipoplex formation protects the siRNA in the lipoplex from 
degradation, and that it is released upon reduction by 
glutathione (see section 2.4).191 The cysteine thiol in EHCO 
(85a) can also be used to enhance selective delivery, for 
example by maleimide conjugation to a PEG-ylated peptide, to 
target cancer cells in wich the bombesin receptor is 
overexpressed.192 The results for these lipopeptides have 
recently been reviewed.193 
4. Asymmetric Geminis and Beyond 
4.1. Gemini surfactants with chiral spacers 
Some cationic gemini surfactants bear one or more chiral 
centers in the spacer group, which can lead to asymmetry in 
the molecular structure. Tartaric acid has a 4C-skeleton with 2 
chiral centres. In an early example (Figure 12),194 the hydroxy 
groups of the L- or (R,R)-enantiomer were esterified with 
palmitic acid, while the carboxylic acid groups were linked by 
an amide bond to one of the amine groups of 1,2-
diaminoethane (86a), the -amino group of the amino acid 
lysine (86b), or a combination of both (86c). Compared to the 
other gemini surfactants studied in the European Network on 
Gemini Surfactants (ENGEMS) project (see below), the activity 
of the compounds 86b and 86c in the transfection of CHO-K1 
cells with luciferase plasmid DNA was moderate, while the 
toxicity, disappointingly, was more than average; compound 
86a was not active at all. More recently, a set of novel geminis 
based on tartaric acid, with the carboxylic acid groups 
esterified with alkyl (C12, 87a; C16, 87b) alcohols, and the 
hydroxyl groups with aminocaproic acids was investigated in 
Hek293T and HeLa cells,195 and found to give GFP expression 
comparable to or better than DC-Chol 8a and DOTAP 2b, with 
significantly lower toxicity. The efﬁciencies of the mixed 
aggregates composed of the neutral helper lipid 1,2-
dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and the 
stereoisomers of the cationic dimeric surfactant with 2 chiral 
centres in the spacer, 2,3-dimethoxy-1,4-bis(N-hexadecyl-N,N-
dimethylammonium) butane dibromide 88 (88a, (2S,3S); 88b 
(2R,3R); 88c (2S,3R), as transfection vectors were tested using 
the eGFP coding plasmid and COS-1 cells.196 In these systems, 
only 88c was more efficient than Fugene, and it also showed 
the lowest toxicity, whereas the half-gemini analogue of 88, 
consisting of one of the surfactant tails and head groups with a 
2-methoxyethyl group instead of the spacer, had no 
transfection activity at all. 
Gemini-like amphiphilic peptides consisting of a peptide 
spacer with the N- and C-termini appended with hydrophobic 
groups are also to be considered ‘geminoids’.119 As an 
example, the SPKR peptide (89-SPKR, Figure 12, with R1, R2, R3, 
R4 representing the Ser, Pro, Lys and Arg side chains, 
respectively) inspired by biological nucleic acid binding 
motifs,50,197 was appended with unsaturated (oleoyl/oleyl) 
alkyl tails. The versatility of the chemical approach allowed 
peptides related to SPKR to be studied, and it was found that 
the Pro and at least one of the cationic (Lys, Arg) residues are 
essential for the biological activity. 89-SPKR and the analogue 
89-APKR showed excellent plasmid DNA transfection of HeLa 
and Hek293T cells with GFP, and quenching of GFP by siRNA in 
1207 human bladder carcinoma cells transfected with GFP, 
with only a moderate cytotoxic effect. Importantly, this can be 
achieved without the addition of a lysogenic helper lipid, 
provided that the lipid tails contain unsaturations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Geminis with chiral spacers. 
 
Analogues of the gemini amphiphilic peptides 85193 in 
which a lysine residue (K) is connected to other amino acids at 
both ( and ) amino groups as in 90 and 91 are also 
asymmetric and fall under the geminoid definition. Of the 2 
ethylenediamine derivatives EKHCO (90a) and EHHKCO (90b), 
the hemolytic activity of the former showed the largest 
increase at lower pH (5.5) and displayed the larger transfection 
activity, at N/P = 12 for U87 glioblastoma cells with pCMV-
luciferase.198 The derivatives 91 with the Sp headgroup (Figure 
3) were studied in the silencing of the U87-Luc cells with N/P = 
12.199 For the compounds without -Ala (z = 0), the activity 
increased in the series 91c < 91d < 91a < Lipofectamine 2000 < 
91c; the activities of the -Ala (z = 1) containing analogues 
98d-h were slightly lower and followed the same order, except 
for 91h which was the most active of all compounds 91. 
 
4.2. Lipidoids 
New cationic lipids for transfection have not only been 
explored by design but also by combinatorial approaches. In 
one such approach, a number of polyamines have been 
reacted with acrylamides with amine residues of varying chain 
length (Figure 13A), and the crude products, coined ‘lipidoids’, 
tested for their activity in the silencing of HeLa cells 
transfected with luciferase by siRNA.200 Not surprisingly, some 
gemini products, such as 92a (64N-16) and its C15-analogue, 
were found to be very effective. Interestingly, some of the 
products of more complex amines and acrylamides with 
shorter (C12) tails, such as 98N-12, turned out to be even more 
active, in particular with 5 tails attached (92b). In combination 
with HO-Chol and PEG-lipid, this compound was particularly 
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effective in silencing the expression of the blood-clotting 
Factor VII, which can be detected in serum, by mouse 
hepatocytes. In a formulation with HO-Chol and PEG-lipid, 92b 
could also silence the expression of apolipoprotein by 
hepatocytes in cynomolgus monkeys; the mass of material 
relative to the siRNA in this experiment was approx. one third, 
with fewer components, of that in the aforementioned 
experiments67 with SNALP with 3b.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Lipidoids from A) acrylates, B) epoxides, C) rings.  
 
In another combinatorial study involving acrylate esters in 
addition to acrylamides, the methoxy compound 93a was 
found to be most active in luciferase silencing in HeLa cells, 
with however low cell viability.201 The result of factor VII 
silencing in mice was better for the alcohol 93b, with > 80 % 
knockdown at 12:1 lipid/siRNA weight ratio. In another study, 
the combination of the amide 93c with the C13-acrylate 
analogue of 93b (98O-13), which are each individually not 
active, was found to be synergistic in this factor VII silencing.202 
The bioreducible analogue 93e with an S-S bond in the acrylate 
was found to be very effective in silencing GFP in MDA-MB-231 
cells expressing this protein.203 
In the exploration of more combinations of amines with 
acrylate esters, it was found that lipid nanoparticles (LNPs) of 
DSPC (1d), HO-Chol, PEG-lipid and any of the lipidoids 94a, 94c, 
and 94d were also very active.204 Based on the result that the 
optimum alkyl tail length and substitution number were 12-13 
and 4, respectively, the next generation of lipidoids was 
developed within the same study, which yielded 94e as the 
most effective compound. The most active lipidoids in the 
silencing of glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) in human colorectal adenocarcinoma (Caco-2) cells 
were 94b, 94d and 94f.205,206 The 3-tailed version of 94b was 
also applied in the silencing of the anti-aptotic protein Mcl1, 
which resulted in apoptosis of mantle cell lymphoma cells,207 
and of tumor necrosis factor  in a macrophage-fibroblast 
model for diabetic foot ulcers.208 
In another combinatorial approach, amines were reacted 
with racemic alkyl epoxides of varying tail lengths (Figure 13B) 
to give the substituted aminoalcohol products 95 as mixtures 
of diastereomers.209 Following initial screening by silencing of 
luciferase in HeLa cells, the compounds 95a-c were identified 
as being most effective in factor VII silencing in mouse 
hepatocytes, with no evidence of adverse effects. In a 
formulation with DSPC, HO-Chol, and PEG, compound 95c was 
found to be more potent by two orders-of-magnitude than the 
best acrylamide lipidoid 92b. For the correlation between 
activity in vitro and in vivo, the RNA entrapment efficiency had 
a higher predictive value than the zeta potential and the 
particle size, provided that the latter was < 200 nm.210 In a 
microscopic study of the transfection by LNPs based on 95c of 
mouse embryonic fibroblasts with or without NPC1 (Niemann-
Pick type C1 glycoprotein), it was found that transfection was 
more efficient without NPC1, implying that this protein is 
responsible for exocytosis of 70 % of the nucleotide.211 In a 
study where 95c-LNP loaded with m-RNA for erythropoietin 
(EPO) were intravenously injected in mice, the EPO level in 
serum was raised by including the classical helper lipid DOPE 
(1a) instead of DSPC (1d) in the formulation.212 LNPs with 
lipopeptide lipidoids are called lipopeptide nanoparticles 
(LPNs). In a study where amine groups incorporated in amino 
acid derivatives were reacted by reductive amination, Michael 
addition to acrylate esters, and epoxide opening, the 
particularly effective compound cKK-E12 (95d), derived from 
the reaction of diketopiperazine of the amino acid lysine with 
the C12-epoxide, was found to be particularly effective and 
selective in the silencing of factor VII in mouse hepatocytes, 
also when compared to 92b and 95c.213 LPNs based on 95d 
were also successfully applied to deliver mRNA vaccines to B 
lymphocytes of the immune system in the spleen of mice to 
enhance their cytotoxic response to a melanoma tumor.214 In a 
study on the transfection of mice with the mRNA for EPO, the 
activity of the linoleyl analogue OF-02 (95e) was even 
higher.215  
Lipidoids have also been used with DNA, for example 14N-
87 (92d), which was more active than the standard 
Lipofectamine 2000 in the transfection of HeLa cells with β-
galactosidase.216 Related to the diketopiperazine platform of 
95d is the triazine in 96, which was applied in simultaneous 
transfection of pDNA and siRNA, viz. expression of GFP and 
silencing of luciferase in HeLa cells.217 
5. Conclusions and Outlook 
The past decade has seen tremendous progress in the 
development, by design and synthesis as well as combinatorial 
approaches, of lipid-based vectors for DNA and RNA delivery. 
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In this review, the emphasis was on multivalency and gemini 
and gemini-like surfactants, which proved to be more effective 
than their single head group/single tail counterparts in many 
(but not all) cases where a comparison could be made. The 
spacer/linker region offers an important additional source of 
variation/optimization in geminis that is not available to 
classical surfactants.  
In the design of vectors, many aspects of molecular and 
aggregate structure must be considered. Electrostatics must 
be balanced with respect to the interaction with the 
polynucleotide and the target cell; the lipid should preferably 
be biodegradable and its positive charge dispersed to minimize 
cytotoxicity. Advantage can be taken of concepts from biology, 
such as peptide sequences for DNA binding, cell-penetration, 
and nuclear localization, as well as recognition of 
carbohydrates by cellular receptors. In our review, the 
emphasis has been more on the exploration of chemical space, 
but it should be noted that insights in physicochemical 
concepts, such as surface charge density, effective charge 
density, lipoplex polymorphism and fusogenicity have also 
been developed; their impact on nuclear acid complexation, 
cellular uptake, endosomal escape, cytoplasmic mobility, and 
nuclear entry has been reviewed elsewhere.39,113,218,219 
Cationic lipids already are used in laboratories for biological 
research purposes on a large scale, and recent surveys37,220 
mention clinical trials with liposomes or LNPs for various 
therapies, viz. with plasmid DNA for (among others) cystic 
fibrosis, various lung cancers, various squamous cell 
carcinomas, glioblastoma, and with siRNA for amyloidosis, 
muscular dystrophy, neuroendocrine tumor and 
adrenocortical carcinoma, liver and pancreatic cancer, and 
hepatic fibrosis. 
Cystic fibrosis is of special interest since it is the most 
frequent lethal recessive congenital disease in Caucasians, 
with a carrier frequency of 1/30.221  The genetic defect, viz. the 
Cystic fibrosis transmembrane conductance regulator (CFTR), 
has been known for almost 30 years, it is monogenic, and the 
lungs are easily accessible; in spite of this, no gene therapy is 
available to date, partly because the thickened mucus, which is 
an important feature of this condition, presents an additional 
barrier to transfection.222 The lipid used in the most recent 
clinical trial,223 GL-67 8b, resulting from modification of DC-
Chol 8a with Sp,224 and its formulation with DOPE for the 
aerosol delivery of functional were also developed some time 
ago.225  
Quite recently, CRISPR-Cas (Clustered Regularly 
Interspaced Short Palindromic Repeats and associated system) 
has emerged as a promising technique to proceed beyond the 
addition of genes as in gene therapy described above, viz. to 
repair genes in the cell nucleus.226 It is based on delivery of 
CRISPR/CAS9 and guide RNA molecules which allows efficient 
editing of specific gene sequences, and can be applied to 
stem/progenitor cells in clinical applications. Like gene 
therapy, this requires that nucleotides are brought in the 
cell;227 this can be achieved for mammalian cells with a 
virus,228,229 but also by non-viral vectors230 such as polymeric 
and hybrid microcarriers, made of degradable polymers such 
as polypeptides and polysaccharides and modified by silica 
shell,231 and by electroporation as in the example of a human 
embryo.232 Cationic lipids have also been used for this 
purpose, such as the aforementioned bioreducible acrylate-
derived lipid 92e203 in the case of the delivery of a protein-RNA 
adduct in HeLa-DsRed cells,233 and the lipid with C3 symmetry 
97 in the delivery of CRISPR-Cas9 mRNA and single-guide RNA 
in C57BL/6 mice.247  
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Table S1. Targeted cells in the studies included in this review (ATCC,  
ATCC or the American Type Culture Collection). 
Name Cell type 
1207 Human urinary bladder carcinomaS1  
1321N1 Human astrocytoma 
A549 Human lung adenocarcinoma epithelial cells (ATCC 
CCL185) 
BHK (IR-780) Baby hamster kidney, Syrian, fibroblast a 
B 
lymphocytes 
B lymphocytes of the immune system in the spleen 
of mice 
BNL-CL2 murine embryonal  hepatocytes (ATCC TIB-73) 
BT-474 human breast ductal carcinoma (ATCC HTB-20) 
C2C12 mouse myogenic/myoblast  (WT) (ATCC CRL-1772) 
CaCo-2 Human epithelial colorectal adenocarcinoma 
(ATCC HTB-37) 
CHO-K1, -K1, 
-CHO-DG44 b) 
Chinese hamster ovary (epithelial, ATCC CCL-61) 
COS-1, COS-7 African Green monkey kidney ﬁbroblast-like cells 
(ATCC CRL1650, ATCC1651) SV40T+ 
CV-1 cells African green monkey, parent to COS (ATCC CCL-
70) 
NCI-H460 Human large cell carcinoma  (ATCC HTB177) 
HEK-293, -
HEK 293T/17 
Human embryonic kidney epithelial (ATCC CRL-
1573)/ CRL-11268) 
HeLa Human cervical epithelial carcinoma cells 
(in most labs 229, ATCC CCL-2.1) 
HepG2, 
Hep3B 
Human hepatocellular carcinoma (ATCC HB-8065)/ 
HB-8064) 
HT-29 human colon adenocarcinoma (ATCC HTB-38) 
HT-1080 human fibrosarcoma (ATCC CCL-121) 
K-562 human lymphoblastoma (ATCC CCL-243)  
L-929  
(NCTC cl929) 
mouse adipose tissue derived spont. (ATCC CCL-1) 
MCF-7 human breast cancer, epithelial 
MDA-MB 
(231) 
human breast cancer cell line, epithelial ATCC HTB-
26 
MEF mouse embryonic fibroblast a 
MG-63 human osteosarcoma (ATCC CRL-1427) 
MOPC 315 Mouse B-cell lymphoma (ATCC TIB-23) 
NCI-H23 human non-small lung cancer cell line (ATCC CRL-
5800 )  
Neuro2A mouse neuroblastoma (ATCC CCL-131) 
NIH/313 murine immortalized fibroblast (ATCC CRL-1658) 
OVCAR-3 Human ovarian cancer, epithelial  (ATCC HTB-161) 
PAM 212 murine keratinocytes a 
RD-4 human rhabdomyosarcoma cell line a 
Sf 1Ep cottontail rabbit epithelial cells (ATCC CCL-68) 
U-251, U-343 human glioblastoma a 
U-373 MG human glioblastoma c 
U-87 MG human glioblastoma (ATCC HTB-14 ) 
S1) D. Chopin, R. Barei-Moniri, P. Maillé, M.-A. Le Frère-Belda, B. 
Muscatelli-Groux, N. Merendino, L. Lecerf, A. Stoppacciaro, F. 
Velotti, Am. J. Pathol. 2003, 162, 1139-1149 
a) no further details known 
b) not in ATCC 
c) withdrawn by ATCC, possibly identical with 271 
 
 
 
